Showing results (81-90 of 324) with videos related to
Sort By:
Pageof 33
Molecular Oncology|October 30, 2012
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinibMing-Hung Huang, Jih-Hsiang Lee, Ya-Ju Chang, et al.The Oncologist|July 25, 2012
Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based studyZhong-Zhe Lin, Wen-Yi Shau, Yu-Yun Shao, et al.Expert Review of Anticancer Therapy|March 20, 2013
Diarrhea associated with afatinib: an oral ErbB family blockerJames Chih-Hsin Yang, Noemi Reguart, Jana Barinoff, et al.Anti-Cancer Drugs|September 1, 2007
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinomaChia-Chi Lin, Kun-Huei Yeh, Chih-Hsin Yang, et al.Plos One|March 26, 2015
Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cellsMei-Chuan Tang, Mei-Yi Wu, Ming-Hung Hwang, et al.Future Oncology (London, England)|February 14, 2022
PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancerRachel Woodford, Deborah Zhou, Sarah J Lord, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2013
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1)Vera Hirsh, Jacques Cadranel, Xiuyu Julie Cong, et al.Chest|July 30, 2011
Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatmentKuei-Pin Chung, Yen-Tsung Huang, Yih-Leong Chang, et al.Lung Cancer (Amsterdam, Netherlands)|September 14, 2010
Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutationsJenn-Yu Wu, Shang-Gin Wu, Chih-Hsin Yang, et al.Oncology|July 16, 2005
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatmentChih-Hsin Yang, Min-Chun Chen, Ann-Lii Cheng, et al.Pageof 33